Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines - Implications for clinical use

Onkologie

Volumn 28, Issue 10, 2005, Pages 482-488

  Voigt, Wieland ^a   Pickan, Volker ^a   Pfeiffer, Claudio ^a   Mueller, Thomas ^a   Simon, Heike ^a   Arnold, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Colorectal carcinoma; Drug interaction; Oxaliplatin; Testicular cancer; Thyroid carcinoma; ZD1839

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; OUTCOMES RESEARCH; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TESTIS CANCER; THYROID CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; LETHAL DOSE 50; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 26444466722     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087344     Document Type: Article

References (25)

1. Wells A: EGF receptor. Int J Biochem Cell Biol 1999;31:637-643.
2. Carpenter G: The EGF receptor: a nexus for trafficking and signaling. Bioessays 2000;22:697-707.
3. Aaronson SA: Growth factors and cancer. Science 1991;254:1146-1153.
4. Vanhoefer U: Novel molecular approaches in the therapy of advanced colorectal carcinoma. Onkologie 2003;26(Suppl 7):70-4.
5. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3(12 Pt 2):2703-7.
6. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
7. Sirotnak FM: Studies with ZD1839 in preclinical models. Semin Oncol 2003;30(1 Suppl 1):12-20.
8. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063.
9. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-235.
10. Grothey A, Schmoll H-J: New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001;13:275-286.
11. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3747.
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
13. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Resell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
14. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Resell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
16. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000;6:2087-2093.
17. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ: Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003;63:513-521.
18. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N: In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 1989;49:4098-4102.
19. Drewinko B, Dipasquale MA, Yang LY, Barlogie B, Trujillo JM: The synergistic lethal interaction of cis-diamminedichloroplatinum and natural nucleosides is related to increased DNA cross-links. Chem Biol Interact 1985;55:1-12.
20. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Jr., Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
21. Xu JM, Azzariti A, Colucci G, Paradiso A: The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 2003;52:442-448.
22. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89:341-343.
23. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA: Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10:7764-7774.
24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
25. Extra JM, Marty M, Brienza S, Misset JL: Pharmakokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25:13-22.